Inovio Pharmaceuticals has reported promising data from the preclinical studies of its Covid-19 vaccine candidate, IN0-480, in mice and guinea pigs.
The candidate was found to have generated ‘robust’ neutralising antibodies and T cell responses against SARS-CoV-2, the novel coronavirus that causes Covid-19.
Inovio and its partners at The Wistar Institute, the University of Texas, Public Health England, Fudan University and Advaccine have published these findings in Nature Communications journal.
Inovio Pharmaceuticals R&D senior vice-president and Covid-19 vaccine development team lead Dr Kate Broderick said: “These positive preclinical results from our Covid-19 DNA vaccine (INO-4800) not only highlight the potency of our DNA medicines